Review highlights immunotherapy's promise to improve survival outcomes in resectable non-small-cell lung cancer, suggesting its critical role in multimodal therapy.
Key Points
Integration of immunotherapy in resectable non-small-cell lung cancer appears to improve survival outcomes, bringing new hope to patients.
Clinical trials have shown that immunotherapy can reduce recurrence rates in stages of non-small-cell lung cancer, increasing treatment efficacy.
The review examines various aspects of immunotherapy including mechanisms of action and clinical implementation challenges.
Future directions in immunotherapy may address unanswered questions about its optimal integration in multimodal therapy.